For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku: Sales Up 0.9% to ¥63.5 Bil. Driven by Cialis, Lunabell
June 6, 2011
- Some GE Houses to Delay Listing Actos Generics for 1 Year
June 6, 2011
- Sales Up 33.1% Driven by CMO Business: CMIC
June 6, 2011
- Sawai to Launch Actos Generics with Full Indications in June
June 6, 2011
- Cervarix Ranked No. 1 in GP Market in March: RepTrack Survey
June 6, 2011
- Towa Ready to Launch Generic Actos with Full Indications
June 6, 2011
- Daiichi Sankyo, AZ to Copromote Denosumab in Japan
June 6, 2011
- Toyota Tsusho to Represent GHL in Japan for Biosimilars Contract Manufacturing Service
June 6, 2011
- Shionogi: Net Profits Down 48.2% due to Earthquake, US Restructuring
May 30, 2011
- Ajinomoto, Mochida to Codevelop Fixed Dose CCB + ARB Combination from PIII
May 30, 2011
- Taisho: Operating Profits Up 27% due to Decreases in SGA Expenses
May 30, 2011
- Sales Down 0.5% due to Slump of Existing Products: Ono
May 30, 2011
- Glaucoma Treatments Drive Business: Santen
May 30, 2011
- PIII Clinical Trial of Lu AA21004 for MDD Starts in Japan: Takeda
May 30, 2011
- Otsuka Announces 1st Midterm Management Plan
May 30, 2011
- BI, Eli Lilly Obtain Approval for Linagliptin in US
May 30, 2011
- Takara Bio Aims for Sales of \22.7 Bil. in FY2013
May 30, 2011
- Terumo Starts Domestic Clinical Study of Acetaminophen
May 30, 2011
- Mediceo: Yakkasa Reduction Rate of Just 0.5 Points in FY2010
May 30, 2011
- Sales Up 5.6% for Ethical Drugs in March Following Disaster: Crecon Research & Consulting
May 30, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…